Table 4:

Significant correlations of baseline levels of plasma proteins (left panel) or changes in plasma protein levels (right panel) with improvement in DAS28-4[CRP] during 3-month treatment with tofacitinib and csDMARDs. Correlations for a change in protein levels were analyzed only for proteins that showed statistically significant (P < 0.05) and minimum 20% difference by tofacitinib treatment.

Protein
	Level at baseline		Decrease during treatment
	r	P	r	P
IL-6	0.612 (0.141–0.899)	0.012	0.639 (0.106–0.918)	0.008
TNFSF14			0.524 (0.027–0.867)	0.037
CCL-11	−0.553 (−0.845 to 0.066)	0.026
DNER	−0.514 (−0.847 to 0.063)	0.042

Spearman correlation coefficients (r) and confidence intervals (CI) calculated with bootstrapping are shown. Empty spaces denote correlations that were not significant (P > 0.05). Composite disease activity score for 28 joints based on C-reactive protein level (DAS28-4[CRP]); conventional systemic disease-modifying antirheumatic drug (csDMARD); interleukin (IL); tumor necrosis factor superfamily member 14 (TNFSF14); C-C motif chemokine 11 (CCL-11); delta and Notch-like epidermal growth factor-related receptor (DNER).